Angiotensin ii receptor blockers, steroids ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Angiotensin ii receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (aster trial). An anocef study
Auteur(s) :
Ursu, R. [Auteur]
Thomas, L. [Auteur]
Psimaras, D. [Auteur]
Chinot, O. [Auteur]
Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Ricard, D. [Auteur]
Charissoux, M. [Auteur]
Cuzzubbo, S. [Auteur]
Sejalon, F. [Auteur]
Quillien, V. [Auteur]
Hoang-Xuan, K. [Auteur]
Ducray, F. [Auteur]
Portal, J.-J. [Auteur]
Tibi, A. [Auteur]
Mandonnet, E. [Auteur]
Levy-Piedbois, C. [Auteur]
Vicaut, E. [Auteur]
Carpentier, A. F. [Auteur]
Thomas, L. [Auteur]
Psimaras, D. [Auteur]
Chinot, O. [Auteur]
Le Rhun, Emilie [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Ricard, D. [Auteur]
Charissoux, M. [Auteur]
Cuzzubbo, S. [Auteur]
Sejalon, F. [Auteur]
Quillien, V. [Auteur]
Hoang-Xuan, K. [Auteur]
Ducray, F. [Auteur]
Portal, J.-J. [Auteur]
Tibi, A. [Auteur]
Mandonnet, E. [Auteur]
Levy-Piedbois, C. [Auteur]
Vicaut, E. [Auteur]
Carpentier, A. F. [Auteur]
Titre de la revue :
European journal of cancer (Oxford, England . 1990)
Nom court de la revue :
Eur. J. Cancer
Numéro :
109
Pagination :
129-136
Date de publication :
2019-02-01
ISSN :
1879-0852
Mot(s)-clé(s) :
Losartan
Steroids
Peritumoural oedema
Angiotensin receptor blockers
Glioblastoma
Steroids
Peritumoural oedema
Angiotensin receptor blockers
Glioblastoma
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: Glioblastomas (GBMs) induce a peritumoural vasogenic oedema impairing functional status and quality of life. Steroids reduce brain tumour-related oedema but are associated with numerous side-effects. It was ...
Lire la suite >BACKGROUND: Glioblastomas (GBMs) induce a peritumoural vasogenic oedema impairing functional status and quality of life. Steroids reduce brain tumour-related oedema but are associated with numerous side-effects. It was reported in a retrospective series that angiotensin receptor blockers might be associated with reduced peritumoural oedema. The ASTER study is a randomised, placebo-controlled trial to assess whether or not the addition of Losartan to standard of care (SOC) can reduce steroid requirement during radiotherapy (RT) in patients with newly diagnosed GBM. PATIENTS AND METHODS: Patients with a histologically confirmed GBM after biopsy or partial surgical resection were randomised between Losartan or placebo in addition to SOC with RT and temozolomide (TMZ). The primary objective was to investigate the steroid dosage required to control brain oedema on the last day of RT in each arm. The secondary outcomes were steroids dosage 1 month after the end of RT, assessment of cerebral oedema on magnetic resonance imaging, tolerance and survival. RESULTS: Seventy-five patients were randomly assigned to receive Losartan (37 patients) or placebo (38 patients). No difference in the steroid dosage required to control brain oedema on the last day of RT, or one month after completion of RT, was seen between both arms. The incidence of adverse events was similar in both arms. Median overall survival was similar in both arms. CONCLUSIONS: Losartan, although well tolerated, does not reduce the steroid requirement in newly diagnosed GBM patients treated with concomitant RT and TMZ. Trial registration number NCT01805453 with ClinicalTrials.gov.Lire moins >
Lire la suite >BACKGROUND: Glioblastomas (GBMs) induce a peritumoural vasogenic oedema impairing functional status and quality of life. Steroids reduce brain tumour-related oedema but are associated with numerous side-effects. It was reported in a retrospective series that angiotensin receptor blockers might be associated with reduced peritumoural oedema. The ASTER study is a randomised, placebo-controlled trial to assess whether or not the addition of Losartan to standard of care (SOC) can reduce steroid requirement during radiotherapy (RT) in patients with newly diagnosed GBM. PATIENTS AND METHODS: Patients with a histologically confirmed GBM after biopsy or partial surgical resection were randomised between Losartan or placebo in addition to SOC with RT and temozolomide (TMZ). The primary objective was to investigate the steroid dosage required to control brain oedema on the last day of RT in each arm. The secondary outcomes were steroids dosage 1 month after the end of RT, assessment of cerebral oedema on magnetic resonance imaging, tolerance and survival. RESULTS: Seventy-five patients were randomly assigned to receive Losartan (37 patients) or placebo (38 patients). No difference in the steroid dosage required to control brain oedema on the last day of RT, or one month after completion of RT, was seen between both arms. The incidence of adverse events was similar in both arms. Median overall survival was similar in both arms. CONCLUSIONS: Losartan, although well tolerated, does not reduce the steroid requirement in newly diagnosed GBM patients treated with concomitant RT and TMZ. Trial registration number NCT01805453 with ClinicalTrials.gov.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
INSERM
Université de Lille
Université de Lille
Date de dépôt :
2022-06-15T13:58:43Z
2023-04-21T15:04:03Z
2023-04-21T15:04:03Z